Skip to main content

IGM Biosciences, Inc. — key financial figures for fiscal year 2024 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Net Income/Loss (FY2024)
-$195.8M
Total Assets (FY2024)
$265.7M
Total Equity (FY2024)
$48.2M
Cash Flows from Operating Activities (FY2024)
-$153.0M

Source: IGM Biosciences, Inc. 10-K filing (FY2024). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.

Discover Hub-Equity